You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

The State of the Therapeutics in Genitourinary Cancers: Where Are We Moving the Needle?

  • Authors: Neeraj Agarwal, MD; Matthew R. Smith, MD, PhD; Stephen B. Williams, MD, MS, FACS
  • CME / ABIM MOC Released: 6/24/2022
  • Valid for credit through: 6/24/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, urologists, and radiologists.

The goal of this activity is to improve learners knowledge of the latest clinical data presented at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO®) regarding the management of genitourinary (GU) cancers, such as prostate cancer and bladder cancer, and to provide recommendations for integrating the data into clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Key clinical trial data for the treatment of GU cancers reported at 2022 ASCO® Annual Meeting
  • Have greater competence related to
    • Incorporating emerging data into treatment paradigms for patients with GU cancers
  • Demonstrate greater confidence in their ability to
    • Incorporate current trial updates into clinical practice


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Neeraj Agarwal, MD

    Professor of Medicine
    Presidential Endowed Chair of Cancer Research
    Senior Director for Clinical Research Innovation
    Director, Center of Investigational Therapeutics
    Director, Genitourinary Oncology Program
    Huntsman Cancer Institute
    University of Utah
    Salt Lake City, Utah

    Disclosures

    Neeraj Agarwal, MD, has the following relevant financial relationships:
    Consultant or advisor for: Astellas; Astra Zeneca; Aveo; Bayer; Bristol Myers Squibb; Calithera; Clovis; Eisai; Eli Lilly; EMD Serono; Exelixis; Foundation Medicine; Genentech; Gilead; Janssen; Merck; MEI Pharma; Nektar; Novartis; Pfizer; Pharmacyclics; Seagen Inc., formerly Seattle Genetics, Inc.
    Research funding from: Astellas; Astra Zeneca; Bavarian Nordic; Bayer; Bristol Myers Squibb; Calithera; Celldex; Clovis; Eisai; Eli Lilly; EMD Serono; Exelixis; Genentech; Gilead; GlaxoSmithKline; Immunomedics; Janssen; Medivation; Merck; Nektar; New Link Genetics; Novartis; Pfizer; Prometheus; Rexahn; Roche; Sanofi; Seagen Inc., formerly Seattle Genetics, Inc.; Takeda; Tracon

  • Matthew R. Smith, MD, PhD

    Claire and John Bertucci Endowed Chair in Genitourinary Cancers
    Professor of Medicine, Harvard Medical School
    Director, Genitourinary Malignancies Program
    Massachusetts General Hospital Cancer Center

    Disclosures

    Matthew R. Smith, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; Astellas; Bayer; Janssen; Lilly; Pfizer
    Research funding from: Amgen; Arvinas; Bayer; ESSA; Janssen; Lilly; Pfizer

  • Stephen B. Williams, MD, MS, FACS

    Medical Director, High Value Care
    UTMB Health System
    Chief, Division of Urology
    Tenured Professor, Urology and Radiology
    Robert Earl Cone Professorship
    Director of Urologic Oncology
    Director of Urologic Research
    Co-Director of the Surgical Outcomes Research Division
    The University of Texas Medical Branch
    Galveston, Texas

    Disclosures

    Stephen B. Williams, MD, MS, FACS, has no relevant financial relationships.

Editor

  • Victoria Phoenix, BS

    Medical Education Director, Medscape, LLC

    Disclosures

    Victoria Phoenix, BS, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

The State of the Therapeutics in Genitourinary Cancers: Where Are We Moving the Needle?

Authors: Neeraj Agarwal, MD; Matthew R. Smith, MD, PhD; Stephen B. Williams, MD, MS, FACSFaculty and Disclosures

CME / ABIM MOC Released: 6/24/2022

Valid for credit through: 6/24/2023

processing....

Note: In order to facilitate disseminating this educational activity as quickly as possible, the associated slides and transcript will be included ~2-3 weeks after the activity posting date.

Contents of This CME Activity

All sections of this activity are required for credit.

Optimizing Treatment With Second-Generation Antiandrogens in Metastatic Hormone-Sensitive Prostate Cancer

How heavily do you rely on PSA progression as a valid marker of disease progression in men with mHSPC?
Neeraj Agarwal, MD

Update on PARP Inhibitors for the Treatment of Metastatic Prostate Cancer

Will the recent results from the PROpel and MAGNITUDE clinical studies change your clinical practice?
Matthew R. Smith, MD, PhD

Advances in Bladder Cancer

New data are available for adjuvant and intravesical therapies for bladder cancer. Are the data practice changing?
Stephen B. Williams, MD, MS, FACS
 

Learning Feedback Questions

Before you begin, please take this brief survey.